Sangamo completes $50M asset sale to Eli Lilly, files July Chapter 11 operating report

SANGAMO THERAPEUTICS, INC

Completed $50M asset sale to Eli Lilly on 9/4/26; includes STAC-BBB capsid, zinc finger, modular integrase platforms, and prion program ST-506.
July 2026 MOR: cash $16.9M, assets $155.1M, liabilities $97.1M; pre-petition unsecured debt $78.1M, post-petition debt $19.0M.
July operating report: net loss $11.2M for month, cumulative loss $14.9M; G&A $3.8M, reorganization items $4.2M.
Chapter 11 filed 6/23/26; court approved sale 8/20/26; stock delisted from Nasdaq, trades OTC as SGMOQ.

Featured in Daily 8-K Digest

Selected #1 for 2026-09-08. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.